Lung Cancer Drug Zaps Tumor Blood Vessels
Study Finds Vadimezan Plus Chemo Prolongs Survival in Lung Cancer Patients
Lung Cancer Drug: Second Opinion
The results of the vadimezan study represent "a considerable improvement in
survival," says Paul A. Bunn Jr., MD, professor of medicine, James Dudley Chair
in Cancer Research at the University of Colorado, Denver, and executive
director of the International Association for the Study of Lung Cancer.
"Almost every year now, we are getting [new] drugs that improve survival in
lung cancer patients." However, he adds, "we have a long way to go."
In the U.S., about 219,000 new cases of lung cancer were expected to be
diagnosed in 2009, with 159,000 expected deaths from the disease, according to
American Cancer Society estimates. Survival rates depend on the stage, with the
five-year survival rate for stage IV non-small-cell lung cancer just 1%,
according to the society.